Avapro

Avapro is a brand name of irbesartan, approved by the FDA in the following formulation(s):

AVAPRO (irbesartan - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: September 30, 1997
  
  Strength(s): 150MG, 300MG ^[RLD], 75MG
  

Has a generic version of Avapro been approved?

No. There is currently no therapeutically equivalent version of Avapro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avapro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
  Patent 5,270,317
  Issued: December 14, 1993
  Inventor(s): Bernhart; Claude & Breliere; Jean-Claude & Clement; Jacques & Nisato; Dino & Perreault; Pierre & Muneaux; Claude & Muneaux; Yvette
  Assignee(s): Elf Sanofi
  The invention relates to N-substituted heterocyclic derivatives and its salts. These derivatives have the formula ##STR1## in which the substituents are as defined in the specification. Application: Angiotensin II antagonists
  
  Patent expiration dates:
  
  
  • September 30, 2011
    
  
  
  
  • March 30, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing irbesartan
  Patent 6,342,247
  Issued: January 29, 2002
  Inventor(s): Cathy C.; Ku & Omar L.; Sprockel & Beth A.; Lang & Divvakant S.; Desai
  Assignee(s): Sanofi-Synthelabo
  Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.
  
  Patent expiration dates:
  
  
  • June 7, 2015
    
  
  
  
  • December 7, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Avapro Consumer Information (Drugs.com)
• Avapro Consumer Information (Wolters Kluwer)
• Avapro Consumer Information (Cerner Multum)
• Avapro Advanced Consumer Information (Micromedex)
• Avapro AHFS DI Monographs (ASHP)
• Irbesartan Consumer Information (Wolters Kluwer)
• Irbesartan Consumer Information (Cerner Multum)
• Irbesartan Advanced Consumer Information (Micromedex)
• Irbesartan AHFS DI Monographs (ASHP)